alt

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013)

September 10-13, 2013, Denver

Back Home Content Conference Coverage

Highlights from 2013 ICAAC, IDWeek, and EACS Meetings

Latest Positive Pulse Newsletter

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.alt

Read more:

ICAAC 2013: Stribild Is Effective and Well-tolerated in Older People with HIV

The Stribild single-tablet regimen matched both Atripla and boosted atazanavir (Reyataz) in efficacy among people age 50 and older, who responded as well as younger patients, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver. Related studies showed that Stribild had durable efficacy through 3 years and caused fewer central nervous system (CNS) side effects than Atripla.

alt

Read more:

ICAAC Underway This Week in Denver

The 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) kicked off Tuesday and runs throughout the week in Denver. HIVandHepatitis.com will be on site to cover the latest research on HIV and hepatitis B and C.

alt

Read more:

ICAAC 2013: New Integrase Inhibitor GSK1265744 Safe and Well-tolerated in 8 Studies

The investigational HIV integrase inhibitor GSK1265744 was well tolerated with no notable safety concerns in a meta-analysis of 8 studies testing the drug as either a pill or a long-acting injection, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.

alt

Read more:

ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups

The new integrase inhibitor dolutegravir (Tivicay) worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver. Another study found that dolutegravir worked well across sex, race/ethnicity, and age groups.

alt

Read more: